HALIFAX, Jan. 5 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR, NASDAQ: MMIRF), a developer and marketer of rapid diagnostic technology and solutions, announced today that Stephen Sham is retiring as the Chairman of the Board of Directors. Mr. Sham will step down as Chairman and will not seek re-election to the Board of Directors in the coming term.
"I have decided that the time is right for me to retire," said Stephen Sham. "I have completed my role here and I am leaving MedMira in good hands and wish the Company well in its future progress."
"On behalf of everyone at the Company and our Board of Directors I want to thank Stephen for his contributions to MedMira. We are very appreciative of his support and guidance through the years he served as both CEO and Chairman of the Board," said Hermes Chan, president and CEO, MedMira Inc. "Stephen's contributions to MedMira in the past 15 years have played a key role in helping us move forward from a start-up to become an internationally recognized company in the diagnostics industry, and we wish him well in his retirement."
The Company expects to name a successor at its next board meeting after the Annual General Meeting.
About MedMira
MedMira is a leading developer and manufacturer of flow-through rapid diagnostics. The company's tests provide hospitals, labs, clinics and individuals with reliable, rapid diagnosis for diseases such as HIV and hepatitis C in just three minutes. The company's tests are sold under the Reveal(R), MiraWell(R), MiraCare(TM) and Multiplo(TM) brands in global markets. MedMira's rapid HIV test is the only one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. MedMira's corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit MedMira's website at www.medmira.com.
This news release contains forward-looking statements, which involve risk and uncertainties and reflect the company's current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this statement.
%SEDAR: 00013053E